<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="cep" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">cep</book-part-id>
      <title-group>
        <title>Congenital Erythropoietic Porphyria</title>
        <alt-title alt-title-type="alt-title">Synonym: G&#x000fc;nther Disease</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Erwin</surname>
            <given-names>Angelika</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Cleveland Clinic<break/>Cleveland, Ohio</aff>
          <email>erwina@ccf.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Balwani</surname>
            <given-names>Manisha</given-names>
          </name>
          <degrees>MD, MS</degrees>
          <aff>Icahn School of Medicine at Mount Sinai<break/>New York, New York</aff>
          <email>manisha.balwani@mssm.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Desnick</surname>
            <given-names>Robert J</given-names>
          </name>
          <degrees>MD, PhD, FACMG</degrees>
          <aff>Icahn School of Medicine at Mount Sinai<break/>New York, New York</aff>
          <email>robert.desnick@mssm.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <collab>Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network</collab>
          <xref ref-type="author-notes" rid="cep.Tb.an4">*</xref>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn id="cep.Tb.an4">
          <label>*</label>
          <p>See Chapter Notes, <xref ref-type="sec" rid="cep.Acknowledgments">Acknowledgments</xref>.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="created">
          <day>12</day>
          <month>9</month>
          <year>2013</year>
        </date>
        <date date-type="updated">
          <day>7</day>
          <month>4</month>
          <year>2016</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="cda1" document-type="chapter">Congenital Dyserythropoietic Anemia Type I</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="cftd" document-type="chapter">Congenital Fiber-Type Disproportion</related-object>
      <abstract id="cep.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Congenital erythropoietic porphyria (CEP) is characterized in most individuals by severe cutaneous photosensitivity with blistering and increased friability of the skin over light-exposed areas. Onset in most affected individuals occurs at birth or early infancy. The first manifestation is often pink to dark red discoloration of the urine. Hemolytic anemia is common and can range from mild to severe, with some affected individuals requiring chronic blood transfusions. Porphyrin deposition may lead to corneal ulcers and scarring, reddish-brown discoloration of the teeth (erythrodontia), and mild bone loss and/or expansion of the bone marrow. The phenotypic spectrum, however, is broad and ranges from non-immune hydrops fetalis in utero to late-onset disease with only mild cutaneous manifestations in adulthood<italic toggle="yes">.</italic></p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of CEP is supported by the biochemical findings of markedly decreased uroporphyrinogen (URO)-synthase activity in erythrocytes and/or markedly increased levels of urinary uroporphyrin I and coproporphyrin I isomers. The diagnosis is confirmed most commonly by identification of biallelic <italic toggle="yes">UROS</italic> pathogenic variants or on rare occasion by the identification of a hemizygous pathogenic variant in the X-linked gene <italic toggle="yes">GATA1</italic>.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> There is no FDA-approved treatment for CEP or specific treatment for the photosensitivity. The only effective management is prevention of blistering by avoidance of sun and light exposure, including the long-wave ultraviolet light that passes through window glass or is emitted from artificial light sources. Therefore, the use of protective clothing, wrap-around sun glasses, protective window films, reddish incandescent bulbs, filtering screens for fluorescent lights, and opaque sunscreens containing zinc oxide or titanium oxide is recommended. Wound care is necessary to prevent infection of opened blisters; surgical intervention may be necessary; blood transfusions are necessary when hemolysis is significant. Bone marrow transplantation (BMT) is the only cure for CEP and should be considered in children with severe cutaneous and hematologic involvement.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Strict avoidance of sunlight and other long-wave UV light exposure.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Vitamin D supplementation, immunization for hepatitis A and B.</p>
          <p><italic toggle="yes">Surveillance:</italic> Monitor hematologic indices to assess hemolysis every six months. In those receiving transfusions: monitor for hemolysis more frequently and for iron overload. Monitor hepatic function and vitamin D 25-OH every six to twelve months in all patients.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Avoidance of sunlight and UV light (see <italic toggle="yes">Treatment of manifestations</italic>). In those with hepatic dysfunction: avoid drugs that may induce cholestasis.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Presymptomatic diagnosis is warranted in relatives at risk for initiation of early intervention (no phototherapy, strict sun protection) and future monitoring for signs of hemolytic anemia.</p>
          <p><italic toggle="yes">Pregnancy management:</italic> Protective filters for artificial lights should be used in the delivery/operating room to prevent phototoxic damage to the mother during delivery.</p>
          <p><italic toggle="yes">Other:</italic> Neither beta-carotene nor phototherapy with narrow-band ultraviolet B radiation has been beneficial.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>CEP caused by biallelic <italic toggle="yes">UROS</italic> pathogenic variants is inherited in an autosomal recessive (AR) manner. CEP caused by a <italic toggle="yes">GATA1</italic> pathogenic variant is inherited in an X-linked (XL) manner.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>AR CEP.</bold> At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Heterozygotes (carriers) are asymptomatic. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.</p>
            </list-item>
            <list-item>
              <p><bold>XL CEP.</bold> If the mother of an affected male is heterozygous for a <italic toggle="yes">GATA1</italic> pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be heterozygotes and can be either asymptomatic or have a milder phenotype.</p>
            </list-item>
          </list>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="cep.Diagnosis">
        <title>Diagnosis</title>
        <p>Formal diagnostic criteria have not been established for congenital erythropoietic porphyria (CEP).</p>
        <sec id="cep.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Congenital erythropoietic porphyria (CEP) <bold>should be suspected</bold> in individuals with the following clinical and laboratory findings.</p>
          <p>
            <bold>Clinical findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Non-immune hydrops fetalis</p>
            </list-item>
            <list-item>
              <p>Signs of congenital erythropoietic porphyria</p>
              <list list-type="bullet">
                <list-item>
                  <p>Pink to dark red discoloration of the urine (pink or dark red urine-stained diapers are often the first sign in infants)</p>
                </list-item>
                <list-item>
                  <p>Hemolytic anemia</p>
                </list-item>
                <list-item>
                  <p>Severe cutaneous photosensitivity with onset usually in infancy or early childhood</p>
                </list-item>
                <list-item>
                  <p>Blisters and vesicles in light-exposed areas, which are prone to rupture and infection</p>
                </list-item>
                <list-item>
                  <p>Scarring and deformities (photomutilation) of digits and facial features, caused by recurrent blistering, infections, and bone resorption</p>
                </list-item>
                <list-item>
                  <p>In light-exposed areas: friable skin, skin thickening, hypo- and hyperpigmentation</p>
                </list-item>
                <list-item>
                  <p>Reddish-brown discoloration of teeth (fluoresce on exposure to long-wave ultraviolet light), also called erythrodontia</p>
                </list-item>
                <list-item>
                  <p>Corneal ulcers and scarring</p>
                </list-item>
                <list-item>
                  <p>Hypertrichosis of face and extremities</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Laboratory findings.</bold> Markedly increased levels of uroporphyrin I and coproporphyrin I isomers in erythrocytes, urine, or amniotic fluid as well as coproporphyrin I in stool (see <xref ref-type="table" rid="cep.T.biochemical_characteristics_of_con">Table 1</xref>)</p>
          <table-wrap id="cep.T.biochemical_characteristics_of_con" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Biochemical Characteristics of Congenital Erythropoietic Porphyria (CEP)</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Enzyme Defect</th>
                  <th id="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Enzyme Activity&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1"/>
                  <th id="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Uroporphyrin&#x000a0;<sup>I</sup></th>
                  <th id="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Coproporphyrin&#x000a0;<sup>I</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">Uroporphyrinogen III synthase (URO-synthase)&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_2" rowspan="4" valign="middle" align="left" colspan="1">Undetectable to ~10% of normal mean activity in erythrocytes</td>
                  <td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Erythrocytes</td>
                  <td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02191;</td>
                  <td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">&#x02191;</td>
                </tr>
                <tr>
                  <td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Urine</td>
                  <td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02191;</td>
                  <td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">&#x02191;</td>
                </tr>
                <tr>
                  <td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Stool</td>
                  <td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">&#x02191;</td>
                </tr>
                <tr>
                  <td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Amniotic&#x000a0;fluid&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02191;</td>
                  <td headers="hd_h_cep.T.biochemical_characteristics_of_con_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">&#x02191;</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>&#x02191; = markedly elevated</p>
              </fn>
              <fn id="cep.TF.1.1">
                <label>1. </label>
                <p>The deficient activity of uroporphyrinogen III synthase EC 4.2.1.75, encoded by UROS, results in non-enzymatic conversion of hydroxymethylbilane to uroporphyrinogen I, which is then metabolized to coproporphyrinogen I. Coproporphyrinogen I cannot be metabolized further. These metabolites are then oxidized to uroporphyrin I and coproporphyrin I, respectively, which are non-physiologic and pathogenic.</p>
              </fn>
              <fn id="cep.TF.1.2">
                <label>2. </label>
                <p>The assay for the enzyme uroporphyrinogen III synthase is available on a clinical basis and can be used to establish the diagnosis of CEP.</p>
              </fn>
              <fn id="cep.TF.1.3">
                <label>3. </label>
                <p>Amniotic fluid appears red to dark brown. Prenatal diagnosis is also possible by demonstrating markedly deficient URO-synthase activity in cultured amniotic cells or chorionic villi cells [<xref ref-type="bibr" rid="cep.REF.da_khadahmane.2001.180">Da&#x000ef;kha-Dahmane et al 2001</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="cep.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of CEP <bold>is established</bold> by biochemical testing and should be confirmed by identification of biallelic pathogenic variants in <italic toggle="yes">UROS</italic> or, on rare occasion, by the identification of a hemizygous pathogenic variant in the X-linked gene <italic toggle="yes">GATA1</italic> [<xref ref-type="bibr" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</xref>] (<xref ref-type="table" rid="cep.T.summary_of_molecular_genetic_testi">Table 2</xref>). If the diagnosis cannot be established by the results of molecular genetic testing, analysis of URO-synthase activity in erythrocytes can be pursued (<xref ref-type="table" rid="cep.T.biochemical_characteristics_of_con">Table 1</xref>).</p>
          <p>Molecular genetic testing approaches can include <bold>serial single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive</bold>
<bold>genomic testing</bold>.</p>
          <list list-type="bullet">
            <list-item>
              <p>Serial single-gene testing</p>
              <list list-type="bullet">
                <list-item>
                  <p>Typically sequence analysis of <italic toggle="yes">UROS</italic> is performed first, followed by <italic toggle="yes">UROS</italic> gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.</p>
                </list-item>
                <list-item>
                  <p>If no <italic toggle="yes">UROS</italic> pathogenic variants are detected, sequencing of <italic toggle="yes">GATA1</italic> should be considered.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">UROS</italic> and <italic toggle="yes">GATA1</italic> and other genes of interest (see <xref ref-type="sec" rid="cep.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost.</p>
              <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
            </list-item>
            <list-item>
              <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing and genome sequencing may be considered if serial single-gene testing (and/or use of a multi-gene panel that includes <italic toggle="yes">UROS</italic> and <italic toggle="yes">GATA1</italic>) fails to confirm a diagnosis in an individual with features of congenital erythropoietic porphyria. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation).</p>
              <p>For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <table-wrap id="cep.T.summary_of_molecular_genetic_testi" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Congenital Erythropoietic Porphyria (CEP)</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_1_2">Proportion of CEP Attributed to Pathogenic Variants in This Gene</th>
                  <th id="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detected by Test Method</th>
                </tr>
                <tr>
                  <th headers="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_1_3" id="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Sequence analysis&#x000a0;<sup>3</sup></th>
                  <th headers="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_1_3" id="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>4</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">UROS</italic>
                  </td>
                  <td headers="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">~98%&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_1_3 hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">~90%&#x000a0;<sup>6,&#x000a0;7</sup></td>
                  <td headers="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_1_3 hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">~10%&#x000a0;<sup>8</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">GATA1</italic>
                  </td>
                  <td headers="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">~1%&#x000a0;<sup>9</sup></td>
                  <td headers="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_1_3 hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">See footnote 10</td>
                  <td headers="hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_1_3 hd_h_cep.T.summary_of_molecular_genetic_testi_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">None reported</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="cep.TF.2.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="cep" object-id="cep.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="cep.TF.2.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="cep.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="cep.TF.2.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="cep.TF.2.4">
                <label>4. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used can include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="cep.TF.2.5">
                <label>5. </label>
                <p>
                  <xref ref-type="bibr" rid="cep.REF.stenson.2003.577">Stenson et al [2003]</xref>
                </p>
              </fn>
              <fn id="cep.TF.2.6">
                <label>6. </label>
                <p>Missense/nonsense variants, splice site variants, small deletions and small duplications, and an insertion/deletion, all detectable by routine sequencing, have been reported (see <xref ref-type="sec" rid="cep.Molecular_Genetics">Molecular Genetics</xref>).</p>
              </fn>
              <fn id="cep.TF.2.7">
                <label>7. </label>
                <p>Six regulatory variants approximately 200 basepairs upstream of the ATG can be detected by sequencing if the DNA region is included in the analysis.</p>
              </fn>
              <fn id="cep.TF.2.8">
                <label>8. </label>
                <p>Two gross deletions, two gross duplications, and one complex rearrangement have been reported [<xref ref-type="bibr" rid="cep.REF.boulechfar.1992.320">Boulechfar et al 1992</xref>, <xref ref-type="bibr" rid="cep.REF.shady.2002.980">Shady et al 2002</xref>, <xref ref-type="bibr" rid="cep.REF.katugampola.2012a.888">Katugampola et al 2012a</xref>]</p>
              </fn>
              <fn id="cep.TF.2.9">
                <label>9. </label>
                <p>A <italic toggle="yes">GATA1</italic> pathogenic variant (p.Arg216Trp) was identified in three unrelated individuals with CEP and hematological abnormalities [<xref ref-type="bibr" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</xref>, <xref ref-type="bibr" rid="cep.REF.di_pierro.2015.491">Di Pierro et al 2015</xref>].</p>
              </fn>
              <fn id="cep.TF.2.10">
                <label>10. </label>
                <p>Lack of amplification by PCR prior to sequence analysis can suggest a putative (multi)exon or whole-gene deletion on the X chromosome in an affected male; confirmation requires additional testing by gene-targeted deletion/duplication analysis.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="cep.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="cep.Clinical_Description">
          <title>Clinical Description</title>
          <p>In most individuals with congenital erythropoietic porphyria (CEP) severe cutaneous photosensitivity begins in early infancy; the first manifestation is often pink to dark red discoloration of the urine. Hemolytic anemia is common and can be mild to severe, requiring chronic blood transfusions in some. The phenotypic spectrum ranges from severe (non-immune hydrops fetalis) to milder disease (adult-onset with isolated cutaneous manifestations [<xref ref-type="bibr" rid="cep.REF.warner.1992.693">Warner et al 1992</xref>]). (See <xref ref-type="sec" rid="cep.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref> for predictors of disease severity.)</p>
          <p><bold>Skin.</bold> Cutaneous photosensitivity is present at birth or early infancy and is characterized by blistering and increased friability of the skin over light-exposed areas. Bullae and vesicles are filled with serous fluid and are prone to rupture. Secondary infections with scarring and bone resorption (photomutilation) may lead to deformity and disfigurement of fingers, toes, and facial features including the nose, ears, and eyelids. Skin thickening, focal hyper- or hypopigmentation, and hypertrichosis of face and extremities may occur [<xref ref-type="bibr" rid="cep.REF.pohfitzpatrick.1986.291">Poh-Fitzpatrick 1986</xref>].</p>
          <p>Photosensitivity symptoms are provoked mainly by visible light (400-410 nm Soret wavelength) and to a lesser degree by wavelengths in the long-wave UV region. Affected individuals are also sensitive to sunlight that passes through window glass that does not filter long-wave UVA or visible light as well as to light from artificial light sources.</p>
          <p>Unlike the cutaneous manifestations in <related-object link-type="booklink" source-id="gene" document-id="epp-ar" document-type="chapter">erythropoietic protoporphyria</related-object> (EPP), symptoms such as tingling, burning, itching, or swelling usually do not occur in persons with CEP after light exposure.</p>
          <p><bold>Hematologic involvement.</bold> Mild to severe hemolytic anemia with anisocytosis, poikilocytosis, polychromasia, basophilic stippling, and reticulocytosis is common in CEP. Findings also include: the absence of haptoglobin, increased unconjugated bilirubin, and increased fecal urobilinogen [<xref ref-type="bibr" rid="cep.REF.schmid.1955.416">Schmid et al 1955</xref>]. Hemolysis presumably results from the accumulation of uroporphyrinogen I in the erythrocytes (see <xref ref-type="sec" rid="cep.Pathophysiology">Pathophysiology</xref>) [<xref ref-type="bibr" rid="cep.REF.bishop.2006.645">Bishop et al 2006</xref>].</p>
          <p>Those with severe hemolytic anemia often require chronic erythrocyte transfusions, which decreases porphyrin production by suppressing erythropoiesis, but can lead to iron overload and other complications [<xref ref-type="bibr" rid="cep.REF.piomelli.1986.1029">Piomelli et al 1986</xref>].</p>
          <p>Secondary splenomegaly may develop as a consequence of hemolytic anemia. In addition to worsening the anemia, it can also result in leukopenia and thrombocytopenia, which may be associated with significant bleeding [<xref ref-type="bibr" rid="cep.REF.pain.1975.621">Pain et al 1975</xref>, <xref ref-type="bibr" rid="cep.REF.weston.1978.921">Weston et al 1978</xref>, <xref ref-type="bibr" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</xref>].</p>
          <p><bold>Ophthalmologic involvement.</bold> Deposition of porphyrins may lead to corneal ulcers and scarring, which can ultimately lead to blindness. Other ocular manifestations can include scleral necrosis, necrotizing scleritis, seborrheic blepharitis, keratoconjunctivitis, sclerokeratitis, and ectropion [<xref ref-type="bibr" rid="cep.REF.oguz.1993.671">Oguz et al 1993</xref>, <xref ref-type="bibr" rid="cep.REF.venkatesh.2000.314">Venkatesh et al 2000</xref>, <xref ref-type="bibr" rid="cep.REF.siddique.2011.97">Siddique et al 2011</xref>].</p>
          <p><bold>Erythrodontia.</bold> Porphyrin deposition in the teeth produces a reddish-brown color, termed erythrodontia. The teeth may fluoresce on exposure to long-wave ultraviolet light.</p>
          <p><bold>Bone involvement.</bold> Deposition of porphyrins in bone causes mild bone loss (osteopenia on x-ray) due to demineralization [<xref ref-type="bibr" rid="cep.REF.piomelli.1986.1029">Piomelli et al 1986</xref>, <xref ref-type="bibr" rid="cep.REF.laorr.1994.307">Laorr &#x00026; Greenspan 1994</xref>, <xref ref-type="bibr" rid="cep.REF.fritsch.1997.594">Fritsch et al 1997</xref>, <xref ref-type="bibr" rid="cep.REF.kontos.2003.160">Kontos et al 2003</xref>]. It can also cause expansion of the bone marrow, which can lead to hyperplastic bone marrow observed on biopsy [<xref ref-type="bibr" rid="cep.REF.pohfitzpatrick.1986.291">Poh-Fitzpatrick 1986</xref>, <xref ref-type="bibr" rid="cep.REF.anderson.2001">Anderson et al 2001</xref>].</p>
          <p><bold>Vitamin D deficiency.</bold> Individuals with CEP who avoid sunlight are at risk for vitamin D deficiency.</p>
        </sec>
        <sec id="cep.Pathophysiology">
          <title>Pathophysiology</title>
          <p>CEP results from markedly decreased (but not absent) URO-synthase activity (&#x0003c;1 to ~10% of normal). When expressed in vitro, the residual enzyme activity of individual pathogenic variants ranges from less than 1.0% to approximately 35% [<xref ref-type="bibr" rid="cep.REF.desnick.2002.779">Desnick &#x00026; Astrin 2002</xref>].</p>
          <p>URO-synthase, the fourth enzyme in the heme biosynthesis pathway, normally converts hydroxymethylbilane (HMB) to uroporphyrinogen III. When URO-synthase activity is deficient, HMB accumulates primarily in the erythron and is non-enzymatically converted to uroporphyrinogen I. Decarboxylation of uroporphyrinogen I by URO-decarboxylase leads to formation of hepta-, hexa-, and pentacarboxyl porphyrinogen I isomers, with coproporphyrinogen I being the final product. Since coproporphyrinogen oxidase is specific for the III isomer, coproporphyrinogen I cannot be further metabolized to heme and is therefore non-physiologic. Isomer I porphyrinogens are pathogenic when they accumulate in large amounts and are auto-oxidized to their corresponding porphyrins [<xref ref-type="bibr" rid="cep.REF.piomelli.1986.1029">Piomelli et al 1986</xref>, <xref ref-type="bibr" rid="cep.REF.pohfitzpatrick.1988">Poh-Fitzpatrick et al 1988</xref>].</p>
          <p>Porphyrinogen I isomers accumulate in bone marrow erythroid precursors; erythrocytes undergo auto-oxidation, which causes damage of the erythrocytes and hemolysis. Porphyrin I isomers are released into the circulation and deposited in skin, bone, and other tissues as well as excreted in urine and feces [<xref ref-type="bibr" rid="cep.REF.desnick.1998.77">Desnick et al 1998</xref>].</p>
          <p>Urinary porphyrin excretion is markedly increased (100-1000 times normal) and consists mainly of uroporphyrin I and coproporphyrin I, with lesser increases in hepta-, hexa-, and pentacarboxyl porphyrin isomers [<xref ref-type="bibr" rid="cep.REF.fritsch.1997.594">Fritsch et al 1997</xref>]. While isomer I porphyrins are predominant, isomer III porphyrins are also increased.</p>
          <p>Cutaneous photosensitivity with blistering and increased friability occurs because the porphyrins deposited in the skin are photocatalytic and cytotoxic compounds [<xref ref-type="bibr" rid="cep.REF.pohfitzpatrick.1985">Poh-Fitzpatrick 1985</xref>]. Presumably, exposure of the skin to sunlight or other sources of long-wave ultraviolet light in the Soret band (400-410 nm) leads to a phototoxic excitation of the accumulated uroporphyrin I and coproporphyrin I isomers. This results in formation of singlet oxygen and other oxygen radicals, which presumably produce tissue and vessel damage [<xref ref-type="bibr" rid="cep.REF.kaufman.1967.210">Kaufman et al 1967</xref>, <xref ref-type="bibr" rid="cep.REF.bickers.1987.261">Bickers 1987</xref>, <xref ref-type="bibr" rid="cep.REF.dawe.2002.680">Dawe et al 2002</xref>].</p>
          <p>The bone marrow contains much larger amounts of porphyrins (mostly uroporphyrin I and coproporphyrin I) than other tissues and hemolysis is almost always present in persons with CEP. Whether it is accompanied by anemia depends on whether erythroid hyperplasia is sufficient to compensate for the increased rate of erythrocyte destruction, which may vary over time. More severely affected individuals are transfusion dependent.</p>
          <p>Splenomegaly usually develops secondary to hemolysis and can also lead to thrombocytopenia and leukopenia. In addition, porphyrin deposition also occurs in the spleen and to a lesser degree in the liver.</p>
        </sec>
        <sec id="cep.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>The genotype-phenotype correlations that have been established in CEP are largely determined by the amount of residual enzyme activity encoded by the specific mutated alleles.</p>
          <p>The most common <italic toggle="yes">UROS</italic> pathogenic variant, <xref ref-type="table" rid="cep.T.uros_pathogenic_variants_discussed">c.217T&#x0003e;C (p.Cys73Arg)</xref>, is observed in about one third of individuals with CEP.</p>
          <list list-type="bullet">
            <list-item>
              <p>Homozygosity for the c.217T&#x0003e;C (p.Cys73Arg) allele results in less than 1% of normal URO-synthase activity and a severe phenotype which may manifest as non-immune hydrops fetalis [<xref ref-type="bibr" rid="cep.REF.frank.1998.225">Frank et al 1998</xref>, <xref ref-type="bibr" rid="cep.REF.desnick.2002.779">Desnick &#x00026; Astrin 2002</xref>].</p>
            </list-item>
            <list-item>
              <p>Compound heterozygosity for the c.217T&#x0003e;C (p.Cys73Arg) allele and a pathogenic variant that expresses a very low level of residual activity results in a severe or moderately severe phenotype.</p>
            </list-item>
          </list>
          <p>In contrast, individuals with pathogenic variants expressing higher residual activities such as <xref ref-type="table" rid="cep.T.uros_pathogenic_variants_discussed">c.244G&#x0003e;T (p.Val82Phe)</xref> (35% of normal activity in vitro), <xref ref-type="table" rid="cep.T.uros_pathogenic_variants_discussed">c.311C&#x0003e;T (p.Ala104Val)</xref> (7.7% of normal activity in vitro), and <xref ref-type="table" rid="cep.T.uros_pathogenic_variants_discussed">c.197C&#x0003e;T (p.Ala66Val)</xref> (14.5% of normal activity in vitro) have milder phenotypes even if heteroallelic for c.217T&#x0003e;C (p.Cys73Arg) or another pathogenic variant with very low or almost absent residual enzyme activity.</p>
          <p>Determination of genotype-phenotype correlations for erythroid-specific promoter pathogenic variants (see <xref ref-type="sec" rid="cep.Molecular_Genetics">Molecular Genetics</xref>) showed the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Compound heterozygotes with the <xref ref-type="table" rid="cep.T.uros_pathogenic_variants_discussed">c.-203T&#x0003e;C</xref> (reported as -70T&#x0003e;C) allele (2.9% of normal activity in vitro) in combination with the <xref ref-type="table" rid="cep.T.uros_pathogenic_variants_discussed">c.217T&#x0003e;C</xref>
<xref ref-type="table" rid="cep.T.uros_pathogenic_variants_discussed">(p.Cys73Arg)</xref> pathogenic variant led to non-immune hydrops fetalis [<xref ref-type="bibr" rid="cep.REF.solis.2001.753">Solis et al 2001</xref>].</p>
            </list-item>
            <list-item>
              <p>The <xref ref-type="table" rid="cep.T.uros_pathogenic_variants_discussed">c.-223C&#x0003e;A</xref> (-90C&#x0003e;A) allele (8.3% of normal activity in vitro) when in compound heterozygosity with another allele with low residual enzyme activity <xref ref-type="table" rid="cep.T.uros_pathogenic_variants_discussed">(c.673G&#x0003e;A (p.Gly225Ser)</xref>, 1.2% of normal activity in vitro) led to a moderately severe phenotype in one individual [<xref ref-type="bibr" rid="cep.REF.solis.2001.753">Solis et al 2001</xref>].</p>
            </list-item>
            <list-item>
              <p>The two other known erythrocyte-specific promoter pathogenic variants, <xref ref-type="table" rid="cep.T.uros_pathogenic_variants_discussed">c.-209G&#x0003e;A</xref> (-76G&#x0003e;A) and <xref ref-type="table" rid="cep.T.uros_pathogenic_variants_discussed">c.-219C&#x0003e;A</xref> (-86C&#x0003e;A), with high residual activities (53.9% and 43.4% of normal in vitro, respectively) in individuals in whom the second allele was <xref ref-type="table" rid="cep.T.uros_pathogenic_variants_discussed">c.217T&#x0003e;C (p.Cys73Arg)</xref>, led to mild cutaneous disease [<xref ref-type="bibr" rid="cep.REF.desnick.2002.779">Desnick &#x00026; Astrin 2002</xref>].</p>
            </list-item>
          </list>
          <p><bold>Disease modifiers.</bold> The CEP phenotype may be modulated by sequence variants in <italic toggle="yes">ALAS2,</italic> mutation of which typically causes <related-object link-type="booklink" source-id="gene" document-id="epp-xl" document-type="chapter">X-linked protoporphyria</related-object> (XLP)<italic toggle="yes">.</italic> A novel c.1757A&#x0003e;T (p.Tyr586Phe) variant in exon 11 of <italic toggle="yes">ALAS2</italic> was identified in a girl with severe CEP who had biallelic <italic toggle="yes">UROS</italic> pathogenic variants [<xref ref-type="bibr" rid="cep.REF.tofigueras.2011.1443">To-Figueras et al 2011</xref>].</p>
        </sec>
        <sec id="cep.Penetrance">
          <title>Penetrance</title>
          <p>Most biallelic <italic toggle="yes">UROS</italic> pathogenic variants are 100% penetrant. One report to the contrary concerns a Palestinian girl who was asymptomatic (without cutaneous or hematologic signs) despite having a profound deficiency in URO-synthase activity due to homozygosity for the pathogenic missense variant c.139T&#x0003e;C. Four of her sibs, who were homozygous for the same pathogenic variant, had moderate to severe cutaneous disease [<xref ref-type="bibr" rid="cep.REF.ged.2004.589">Ged et al 2004</xref>]. The molecular basis for the apparent non-penetrance in one sib is unknown but possibly involves unknown modifier genes that prevent the phototoxic effects of porphyrin accumulation.</p>
        </sec>
        <sec id="cep.Nomenclature">
          <title>Nomenclature</title>
          <p>Obsolete terms for CEP are: erythropoietic porphyria, congenital porphyria, congenital hematoporphyria, and erythropoietic uroporphyria (G&#x000fc;nther&#x02019;s disease).</p>
        </sec>
        <sec id="cep.Prevalence">
          <title>Prevalence</title>
          <p>CEP is a rare porphyria. To date, more than 200 cases have been reported.</p>
          <p>CEP is pan ethnic and occurs equally in men and women [<xref ref-type="bibr" rid="cep.REF.katugampola.2012b.901">Katugampola et al 2012b</xref>].</p>
        </sec>
      </sec>
      <sec id="cep.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold><italic toggle="yes">UROS</italic></bold>. No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">UROS</italic>.</p>
        <p><bold><italic toggle="yes">GATA1.</italic></bold> Pathogenic variants in this gene are also observed in:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="gata1" document-type="chapter"><italic toggle="yes">GATA1</italic>-related cytopenias</related-object>;</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="diamond-b" document-type="chapter">Diamond-Blackfan anemia</related-object>.</p>
          </list-item>
        </list>
      </sec>
      <sec id="cep.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Other disorders presenting with a congenital erythropoietic porphyria (CEP)-like phenotype are listed in <xref ref-type="table" rid="cep.T.disorders_to_consider_in_the_diffe">Table 3</xref>.</p>
        <table-wrap id="cep.T.disorders_to_consider_in_the_diffe" orientation="portrait" position="anchor">
          <label>Table 3. </label>
          <caption>
            <p>Disorders to Consider in the Differential Diagnosis of Congenital Erythropoietic Porphyria</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1">Disease Name</th>
                <th id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2">Gene(s)</th>
                <th id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="2" valign="middle" colspan="2" align="left" scope="colgroup" headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3">MOI</th>
                <th id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Clinical Features</th>
              </tr>
              <tr>
                <th headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4" id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Overlapping</th>
                <th headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4" id="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Distinguishing</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Porphyria cutanea tarda (PCT) type I (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/176090">176090</ext-link>)</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" colspan="3" align="left" rowspan="1">See footnote 1</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="2" valign="middle" align="left" colspan="1"><list list-type="bullet"><list-item><p>Cutaneous photosensitivity w/blistering &#x00026; friability of skin in sun-exposed areas</p></list-item><list-item><p>Facial hypertrichosis</p></list-item><list-item><p>Discolored urine</p></list-item></list>
</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="2" valign="middle" align="left" colspan="1"><list list-type="bullet"><list-item><p>Usually manifests in adulthood</p></list-item><list-item><p>Distinct biochemical porphyrin profile</p></list-item></list>
</td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="porphyria-ct" document-type="chapter">Porphyria cutanea tarda (PCT) type II</related-object>
                </td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" colspan="2" align="left" rowspan="1">
                  <italic toggle="yes">UROD</italic>
                </td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="hep" document-type="chapter">Hepato-erythropoietic porphyria</related-object>
                </td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" colspan="2" align="left" rowspan="1">
                  <italic toggle="yes">UROD</italic>
                </td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Phenotype similar to PCT</p></list-item><list-item><p>Manifests in early childhood</p></list-item><list-item><p>Discolored urine</p></list-item><list-item><p>Photosensitivity</p></list-item></list>
</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Distinct biochemical porphyrin profile</p></list-item><list-item><p>Developmental delay (in some)</p></list-item></list>
</td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="hcp" document-type="chapter">Hereditary coproporphyria</related-object>
                </td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" colspan="2" align="left" rowspan="1">
                  <italic toggle="yes">CPOX</italic>
                </td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="2" valign="middle" align="left" colspan="1"><list list-type="bullet"><list-item><p>20% of affected individuals experience photosensitivity w/skin blistering in sun-exposed areas</p></list-item></list>
</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="2" valign="middle" align="left" colspan="1"><list list-type="bullet"><list-item><p>Acute (hepatic) porphyria</p></list-item><list-item><p>Acute attacks of abdominal or generalized pain; can be associated w/neurologic symptoms</p></list-item><list-item><p>Incompletely penetrant in absence of environmental inducers</p></list-item><list-item><p>Usually manifests after puberty</p></list-item></list>
</td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="porphyria-var" document-type="chapter">Variegate porphyria</related-object>
                </td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" colspan="2" align="left" rowspan="1">
                  <italic toggle="yes">PPOX</italic>
                </td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Myeloid malignancy</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" colspan="2" align="left" rowspan="1"/>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Elderly adults w/myelodysplastic syndrome may exhibit features of CEP&#x000a0;<sup>2,&#x000a0;3</sup></p></list-item></list>
</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="ebs" document-type="chapter">Epidermolysis bullosa simplex (EBS)</related-object>
                </td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" colspan="2" align="left" rowspan="1">
                  <italic toggle="yes">KRT5<break/>KRT14</italic>
                </td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AD&#x000a0;<sup>4</sup></td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Fragility of skin resulting in nonscarring blisters caused by little/no trauma</p></list-item><list-item><p>Major &#x00026; minor subtypes share common feature of blistering above dermal-epidermal junction at the ultrastructural level</p></list-item></list>
</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="ebj" document-type="chapter">Junctional epidermolysis bullosa (JEB)</related-object>
                </td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" colspan="2" align="left" rowspan="1">
                  <italic toggle="yes">LAMA3<break/>LAMB3<break/>LAMC2<break/>COL17A1</italic>
                </td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Fragility of skin &#x00026; mucous membranes, manifest by blistering w/little or no trauma</p></list-item><list-item><p>Herlitz JEB (classic severe form): blisters present at birth or become apparent in neonatal period</p></list-item><list-item><p>Non-Herlitz JEB: may be mild w/blistering localized to hands, feet, knees, elbows</p></list-item></list>
</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="ebd" document-type="chapter">Dystrophic epidermolysis bullosa</related-object>
                </td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_2 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="2" valign="middle" colspan="2" align="left">
                  <italic toggle="yes">COL7A1</italic>
                </td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Blisters affecting whole body may be present in neonatal period</p></list-item><list-item><p>Oral involvement</p></list-item><list-item><p>Corneal erosions</p></list-item></list>
</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Esophageal erosions</p></list-item><list-item><p>Severe nutritional deficiency &#x00026; secondary problems</p></list-item><list-item><p>&#x0201c;Mitten" hands &#x00026; feet</p></list-item><list-item><p>&#x0003e;90% lifetime risk of aggressive squamous cell carcinoma</p></list-item></list>
</td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">AD</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Blistering, often mild &#x00026; limited to hands, feet, knees, elbows; heals w/scarring</p></list-item></list>
</td>
                <td headers="hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_cep.T.disorders_to_consider_in_the_diffe_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Dystrophic nails possibly the only manifestation</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>MOI = mode of inheritance</p>
            </fn>
            <fn>
              <p>AD = autosomal dominant</p>
            </fn>
            <fn>
              <p>AR = autosomal recessive</p>
            </fn>
            <fn id="cep.TF.3.1">
              <label>1. </label>
              <p>80% of cases are sporadic or acquired (type I PCT). Type I (or sporadic) PCT is characterized by normal URO-decarboxylase activity systemically when affected individuals are asymptomatic. Inhibition of the enzyme activity resulting in PCT can be caused by excessive alcohol intake, hemochromatosis, viral hepatitis (mostly hepatitis C), HIV infection, certain medications, and environmental exposures such as aromatic polyhalogenated hepatotoxins. Treatment consists of eliminating or treating the underlying cause and, if symptoms persist, frequent phlebotomies or therapy with oral low-dose hydroxychloroquine.</p>
            </fn>
            <fn id="cep.TF.3.2">
              <label>2. </label>
              <p><xref ref-type="bibr" rid="cep.REF.fritsch.1997.594">Fritsch et al [1997]</xref>, <xref ref-type="bibr" rid="cep.REF.kontos.2003.160">Kontos et al [2003]</xref>, <xref ref-type="bibr" rid="cep.REF.sarkany.2011.1172">Sarkany et al [2011]</xref></p>
            </fn>
            <fn id="cep.TF.3.3">
              <label>3. </label>
              <p>Affected individuals had normal erythrocyte URO-synthase activities. Presumably, the CEP-like manifestations resulted from genetic or functional changes associated with the bone marrow disorder.</p>
            </fn>
            <fn id="cep.TF.3.4">
              <label>4. </label>
              <p>EBS caused by pathogenic variants in <italic toggle="yes">KRT5</italic> or <italic toggle="yes">KRT14</italic> is usually inherited in an autosomal dominant manner; in rare families, especially those with consanguinity, it can be inherited in an autosomal recessive manner.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="cep.Management">
        <title>Management</title>
        <sec id="cep.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs of an individual diagnosed with congenital erythropoietic porphyria (CEP), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Hematologic indices including reticulocytes and bilirubin (to assess hemolysis) and iron profile (to assess iron storage)</p>
            </list-item>
            <list-item>
              <p>Serum calcium and vitamin D concentrations; bone densitometry</p>
            </list-item>
            <list-item>
              <p>Hepatic function tests</p>
            </list-item>
            <list-item>
              <p>Dermatologic evaluation</p>
            </list-item>
            <list-item>
              <p>Ophthalmologic evaluation</p>
            </list-item>
            <list-item>
              <p>Dental assessment</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
          <p>Urine and erythrocyte porphyrins can be determined periodically after bone marrow transplant as a monitor of engraftment.</p>
        </sec>
        <sec id="cep.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p><bold>Cutaneous photosensitivity.</bold> There is no FDA-approved treatment for this disease or specific treatment for the photosensitivity.</p>
          <p>Currently the only effective treatment is prevention of blistering by avoidance of light exposure, including the long-wave ultraviolet sunlight that passes through window glass or light emitted by fluorescent sources:</p>
          <list list-type="bullet">
            <list-item>
              <p>Sun protection using protective clothing including long sleeves, gloves, and wide-brimmed hats</p>
            </list-item>
            <list-item>
              <p>Protective window films for cars and windows at home as well as at school/work to prevent exposure to UV light</p>
            </list-item>
            <list-item>
              <p>Replacement of fluorescent lights with reddish incandescent bulbs or installation of filtering screens</p>
            </list-item>
            <list-item>
              <p>Reflectant sunscreens containing zinc oxide or titanium dioxide. Note, however, that these may be cosmetically unacceptable and, in any case, do not replace strict avoidance of sun/light exposure.</p>
            </list-item>
          </list>
          <p>Skin trauma should be avoided.</p>
          <p>Wound care is essential to prevent infection of opened blisters. Antiseptic and topical/oral antibiotic treatment may be indicated to avoid progression to osteomyelitis and bone resorption with subsequent mutilation.</p>
          <p>Surgical intervention may be indicated for severe mutilation (repair of microstomia, correction of ectropion, reconstruction of the nose).</p>
          <p>Laser hair removal can be used to treat facial hypertrichosis.</p>
          <p>Note: (1) Beta-carotene has been tried in some individuals but without significant benefit. (2) Phototherapy with narrowband ultraviolet B radiation did not show any benefit.</p>
          <p>
            <bold>Ocular manifestations</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Avoidance of damage to the eyelids and cornea by wrap-around sun glasses</p>
            </list-item>
            <list-item>
              <p>Topical antibiotics for corneal ulcers, scleritis, and blepharitis</p>
            </list-item>
            <list-item>
              <p>Artificial tears and lubricants to help prevent dry eyes in those with ectropion</p>
            </list-item>
            <list-item>
              <p>Corrective surgery of eyelids to help protect the cornea from injury in those with ectropion [<xref ref-type="bibr" rid="cep.REF.katugampola.2012a.888">Katugampola et al 2012a</xref>]</p>
            </list-item>
          </list>
          <p><bold>Bone manifestations.</bold> Bisphosphonates can be considered in individuals with osteoporosis [<xref ref-type="bibr" rid="cep.REF.katugampola.2012a.888">Katugampola et al 2012a</xref>].</p>
          <p>
            <bold>Hemolytic anemia</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Consider blood transfusions when hemolysis is significant.</p>
            </list-item>
            <list-item>
              <p>Chronic transfusions (every 2-4 weeks) with a target hematocrit greater than 35% can suppress erythropoiesis and decrease porphyrin production, which reduces porphyrin levels and photosensitivity [<xref ref-type="bibr" rid="cep.REF.piomelli.1986.1029">Piomelli et al 1986</xref>].</p>
              <p>Note: In those who receive frequent transfusions, the body iron burden can be reduced with parenteral or oral chelators [<xref ref-type="bibr" rid="cep.REF.pohfitzpatrick.1988">Poh-Fitzpatrick et al 1988</xref>].</p>
            </list-item>
            <list-item>
              <p>Iron deficiency induced by treatment with deferasirox improved photosensitivity and hemolysis in one patient [<xref ref-type="bibr" rid="cep.REF.egan.2015.257">Egan at al 2015</xref>].</p>
            </list-item>
          </list>
          <p>Note: Although oral charcoal and cholestyramine were thought to increase fecal loss of porphyrins, a clear clinical benefit has not been shown [<xref ref-type="bibr" rid="cep.REF.tishler.1990.645">Tishler &#x00026; Winston 1990</xref>].</p>
          <p><bold>Bone marrow transplantation (BMT)</bold> is the only cure for CEP and should be considered in children with severe cutaneous and hematologic involvement. Autologous as well as allogeneic stem cell transplants have been performed successfully [<xref ref-type="bibr" rid="cep.REF.thomas.1996.453">Thomas et al 1996</xref>, <xref ref-type="bibr" rid="cep.REF.tezcan.1998.4053">Tezcan et al 1998</xref>, <xref ref-type="bibr" rid="cep.REF.harada.2001.279">Harada et al 2001</xref>, <xref ref-type="bibr" rid="cep.REF.shaw.2001.101">Shaw et al 2001</xref>, <xref ref-type="bibr" rid="cep.REF.dupuisgirod.2005.104">Dupuis-Girod et al 2005</xref>, <xref ref-type="bibr" rid="cep.REF.taibjee.2007.567">Taibjee et al 2007</xref>, <xref ref-type="bibr" rid="cep.REF.faraci.2008.117">Faraci et al 2008</xref>]. The age of children with CEP receiving BMT ranges from younger than one year to 13 years [<xref ref-type="bibr" rid="cep.REF.katugampola.2012b.901">Katugampola et al 2012b</xref>]. Of note, although some of the first individuals with CEP to successfully undergo BMT in childhood should be in their 20s now [<xref ref-type="bibr" rid="cep.REF.thomas.1996.453">Thomas et al 1996</xref>, <xref ref-type="bibr" rid="cep.REF.zixkieffer.1996.217">Zix-Kieffer et al 1996</xref>], no follow-up information is available and the long-term outcome in individuals with CEP post-BMT is unknown.</p>
        </sec>
        <sec id="cep.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>Strict avoidance of sunlight and protection from light are indicated.</p>
        </sec>
        <sec id="cep.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>Vitamin D supplementation is advised as affected individuals are predisposed to vitamin D insufficiency due to sun avoidance.</p>
          <p>Immunization for hepatitis A and B is recommended.</p>
        </sec>
        <sec id="cep.Surveillance">
          <title>Surveillance</title>
          <p>Monitor the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Hematologic indices including iron profile, reticulocyte count, and bilirubin to assess hemolysis every six months</p>
              <p>Note: Individuals receiving transfusion therapy need closer monitoring.</p>
            </list-item>
            <list-item>
              <p>Iron profile on a regular basis to assess for iron overload for those who are transfusion dependent</p>
            </list-item>
            <list-item>
              <p>Hepatic function every six to twelve months</p>
            </list-item>
            <list-item>
              <p>Vitamin D 25-OH levels in all patients whether or not they are receiving vitamin D supplements</p>
            </list-item>
          </list>
        </sec>
        <sec id="cep.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>The following are appropriate:</p>
          <p>Avoidance of sunlight and UV light</p>
          <p>In patients with hepatic dysfunction, avoidance of drugs which may induce cholestasis (e.g., estrogens)</p>
          <p>In patients undergoing surgeries, use of protective filters for artificial lights in the operating room to prevent phototoxic damage [<xref ref-type="bibr" rid="cep.REF.wahlin.2008.1340">Wahlin et al 2008</xref>]</p>
        </sec>
        <sec id="cep.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate at-risk sibs as newborns or infants in order to identify as early as possible those who would benefit from early intervention (no phototherapy, strict sun protection) and future monitoring for signs of hemolytic anemia. Evaluations include:</p>
          <p>Molecular genetic testing if the pathogenic variant(s) in the family are known;</p>
          <p>Biochemical testing for urinary or erythrocyte uroporphyrin I and coproporphyrin I isomer elevation if the pathogenic variants in the family are not known.</p>
          <p>See <xref ref-type="sec" rid="cep.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="cep.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Successful pregnancies in women with CEP resulting in healthy and unaffected children have been described [<xref ref-type="bibr" rid="cep.REF.hallai.2007.622">Hallai et al 2007</xref>, <xref ref-type="bibr" rid="cep.REF.katugampola.2012b.901">Katugampola et al 2012b</xref>].</p>
          <p>Protective filters for artificial lights should be used in the delivery/operating room to prevent phototoxic damage to the mother during delivery [<xref ref-type="bibr" rid="cep.REF.wahlin.2008.1340">Wahlin et al 2008</xref>].</p>
        </sec>
        <sec id="cep.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>To date, gene therapy has been evaluated only in the murine CEP model [<xref ref-type="bibr" rid="cep.REF.de_verneuil.2008.615">de Verneuil et al 2008</xref>, <xref ref-type="bibr" rid="cep.REF.fortian.2011.13127">Fortian et al 2011</xref>, <xref ref-type="bibr" rid="cep.REF.di_pierro.2015.491">Di Pierro et al 2015</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="cep.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="cep.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Congenital erythropoietic porphyria (CEP) caused by biallelic <italic toggle="yes">UROS</italic> pathogenic variants is inherited in an autosomal recessive manner.</p>
          <p>CEP caused by a hemizygous <italic toggle="yes">GATA1</italic> pathogenic variant is inherited in an X-linked manner. Note: To date only three such individuals have been identified [<xref ref-type="bibr" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</xref>, <xref ref-type="bibr" rid="cep.REF.di_pierro.2015.491">Di Pierro et al 2015</xref>].</p>
        </sec>
        <sec id="cep.Risk_to_Family_Members__Autosomal_Re">
          <title>Risk to Family Members &#x02014; Autosomal Recessive Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected individual are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">UROS</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Unless an individual with congenital erythropoietic porphyria has children with an affected individual or a carrier, his/her offspring will be obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">UROS</italic>.</p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier of a <italic toggle="yes">UROS</italic> pathogenic variant.</p>
        </sec>
        <sec id="cep.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">UROS</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="cep.Risk_to_Family_Members__XLinked_Inhe">
          <title>Risk to Family Members &#x02014; X-Linked Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The father of an affected male will not have the disease nor will he be a carrier of the <italic toggle="yes">GATA1</italic> pathogenic variant; therefore, he does not require further evaluation/testing.</p>
            </list-item>
            <list-item>
              <p>Women who have an affected son and another affected male relative are obligate heterozygotes.</p>
            </list-item>
            <list-item>
              <p>If a male is the only affected family member (i.e., a simplex case), the mother may be a heterozygote (carrier) or the affected male may have a <italic toggle="yes">de novo</italic>
<italic toggle="yes">GATA1</italic> pathogenic variant, in which case the mother is not a carrier. The frequency of <italic toggle="yes">de novo</italic>
<italic toggle="yes">GATA1</italic> pathogenic variants is unknown.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband.</bold> The risk to sibs of a male proband depends on the genetic status of the mother:</p>
          <list list-type="bullet">
            <list-item>
              <p>If the mother of the proband has a <italic toggle="yes">GATA1</italic> pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be heterozygotes and can be either asymptomatic or have a milder phenotype with predominantly hematologic abnormalities due to skewed X-inactivation [<xref ref-type="bibr" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</xref>, <xref ref-type="bibr" rid="cep.REF.di_pierro.2015.491">Di Pierro et al 2015</xref>].</p>
            </list-item>
            <list-item>
              <p>If the proband represents a simplex case (i.e., a single occurrence in a family) and if the pathogenic variant cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the general population because of the possibility of maternal germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Affected males transmit the <italic toggle="yes">GATA1</italic> pathogenic variant to:</p>
          <list list-type="bullet">
            <list-item>
              <p>All of their daughters, who will be (heterozygotes) carriers and can be either asymptomatic or have a milder phenotype with predominantly hematologic abnormalities due to skewed X-inactivation [<xref ref-type="bibr" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</xref>, <xref ref-type="bibr" rid="cep.REF.di_pierro.2015.491">Di Pierro et al 2015</xref>];</p>
            </list-item>
            <list-item>
              <p>None of their sons.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> The proband's maternal aunts may be at risk of being carriers and the aunts&#x02019; offspring, depending on their gender, may be at risk of being carriers or of being affected.</p>
        </sec>
        <sec id="cep.Carrier_Heterozygote_Detection_1">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the <italic toggle="yes">GATA1</italic> pathogenic variant has been identified in the proband.</p>
        </sec>
        <sec id="cep.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="cep.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="cep.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>Molecular genetic testing.</bold> Once the <italic toggle="yes">UROS</italic> or <italic toggle="yes">GATA1</italic> pathogenic variant(s) have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for CEP are possible.</p>
          <p><bold>Biochemical genetic testing.</bold> Prenatal diagnosis is also possible by demonstrating markedly deficient URO-synthase activity in cultured amniotic cells or chorionic villi cells, and/or markedly elevated uroporphyrin I and coproporphyrin I concentrations in amniotic fluid (see <xref ref-type="table" rid="cep.T.biochemical_characteristics_of_con">Table 1</xref>).</p>
          <p>Note: It is assumed that an elevation of uroporphyrin I and coproporphyrin I concentrations in amniotic fluid is also present in <italic toggle="yes">GATA1</italic>-related CEP; however, at this time data are insufficient to confirm this hypothesis.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="cep.Resources">
        <title>Resources</title>
      </sec>
      <sec id="cep.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p>
          <bold>
            <italic toggle="yes">UROS</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">UROS</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000375.2">NM_000375.2</ext-link>) has ten exons and two mRNA transcripts, generated by alternative splicing directed from unique housekeeping and erythroid-specific promoters. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="cep" object-id="cep.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> Approximately 50 loss-of-function variants (see <related-object source-id="gene" document-id="cep" object-id="cep.molgen.TA">Table A</related-object>, <bold>HGMD</bold>) have been identified in <italic toggle="yes">UROS</italic>, many of which result in an unstable or functionally severely impaired enzyme. Pathogenic loss-of-function variants include missense and nonsense variants and small deletions and insertions (<xref ref-type="table" rid="cep.T.uros_pathogenic_variants_discussed">Table 4</xref>). Regulatory pathogenic variants are located in intron 1 upstream of the exon 2 ATG.</p>
        <table-wrap id="cep.T.uros_pathogenic_variants_discussed" orientation="portrait" position="anchor">
          <label>Table 4. </label>
          <caption>
            <p><italic toggle="yes">UROS</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.139T&#x0003e;C</td>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ser47Pro</td>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_3" rowspan="6" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000375.2">NM_000375.2</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000366.1">NP_000366.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.197C&#x0003e;T</td>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala66Val</td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.217T&#x0003e;C</td>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys73Arg</td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.244G&#x0003e;T</td>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Val82Phe</td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.311C&#x0003e;T</td>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala104Val</td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.673G&#x0003e;A</td>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly225Ser</td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1 hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2 hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_3" valign="middle" colspan="3" align="left" scope="col" rowspan="1">
                  <bold>Pathogenic variants in the erythroid-specific promoter region</bold>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.-203T&#x0003e;C<break/>(-70T&#x0003e;C)&#x000a0;<sup>2</sup></td>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_2" rowspan="4" valign="middle" align="left" colspan="1">NA</td>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_3" rowspan="4" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000375.2">NM_000375.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">c.-209G&#x0003e;A<break/>(-76G&#x0003e;A)</td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">c.-219C&#x0003e;A<break/>(-86C&#x0003e;A)</td>
              </tr>
              <tr>
                <td headers="hd_h_cep.T.uros_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">c.-223C&#x0003e;A<break/>(-90C&#x0003e;A)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn>
              <p>NA = not applicable.</p>
            </fn>
            <fn id="cep.TF.4.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
            <fn id="cep.TF.4.2">
              <label>2. </label>
              <p>Traditional nomenclature [<xref ref-type="bibr" rid="cep.REF.solis.2001.753">Solis et al 2001</xref>, <xref ref-type="bibr" rid="cep.REF.desnick.2002.779">Desnick &#x00026; Astrin 2002</xref>]</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> The normal gene encodes the enzyme uroporphyrinogen III synthase, which consists of 265 amino acids (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000366.1">NP_000366.1</ext-link>).</p>
        <p><bold>Abnormal gene product.</bold>
<italic toggle="yes">UROS</italic> pathogenic variants result in either a nonfunctional or a partially functional enzyme.</p>
        <p>
          <bold>
            <italic toggle="yes">GATA1</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">GATA1</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_002049.3">NM_002049.3</ext-link>) has five coding exons and two alternative untranslated regions (UTRs) (one 3&#x02019; and one 5&#x02019;). For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="cep" object-id="cep.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> A <italic toggle="yes">GATA1</italic> pathogenic variant (p.Arg216Trp) has been identified in three unrelated individuals with CEP and hematologic abnormalities (thrombocytopenia, dyserythropoietic anemia, beta-thalassemia) [<xref ref-type="bibr" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</xref>, <xref ref-type="bibr" rid="cep.REF.di_pierro.2015.491">Di Pierro et al 2015</xref>].</p>
        <p>See <related-object source-id="gene" document-id="gata1" object-id="gata1.Molecular_Genetics"><italic toggle="yes">GATA1</italic>-Related X-Linked Cytopenia, Molecular Genetics</related-object>, <bold>Pathogenic variants</bold>.</p>
        <p><bold>Normal gene product.</bold> GATA1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_002040.1">NP_002040.1</ext-link>) is a transcription factor that normally regulates the expression of URO-synthase in developing erythrocytes.</p>
        <p>See <related-object source-id="gene" document-id="gata1" object-id="gata1.Molecular_Genetics"><italic toggle="yes">GATA1</italic>-Related X-Linked Cytopenia, Molecular Genetics</related-object>, <bold>Normal gene product</bold>.</p>
        <p><bold>Abnormal gene product.</bold> The p.Arg216Trp pathogenic variant is predicted to dramatically alter the binding of GATA1 to URO-synthase, resulting in significantly reduced (~20% of normal) URO-synthase activity [<xref ref-type="bibr" rid="cep.REF.phillips.2007.2618">Phillips et al 2007</xref>].</p>
        <p>See <related-object source-id="gene" document-id="gata1" object-id="gata1.Molecular_Genetics"><italic toggle="yes">GATA1</italic>-Related X-Linked Cytopenia, Molecular Genetics</related-object>, <bold>Abnormal gene product</bold>.</p>
      </sec>
      <sec id="cep.References">
        <title>References</title>
        <sec id="cep.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="cep.Literature_Cited.reflist0">
            <ref id="cep.REF.anderson.2001">
              <mixed-citation publication-type="book">Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemias and the porphyrias. In: Scriver CR, Beaudet AL, Sly WS, eds. <italic toggle="yes">The Metabolic and Molecular Basis of Inherited Disease.</italic> 8 ed. New York, NY: McGraw-Hill; 2001:2991.</mixed-citation>
            </ref>
            <ref id="cep.REF.bickers.1987.261">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bickers</surname>
                    <given-names>DR</given-names>
                  </name>
                </person-group>
                <article-title>The dermatologic manifestations of human porphyria.</article-title>
                <source>Ann N Y Acad Sci.</source>
                <year>1987</year>
                <volume>514</volume>
                <fpage>261</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">3327430</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.bishop.2006.645">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bishop</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johansson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phelps</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shady</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramirez</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasuda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Uroporphyrinogen III synthase knock-in mice have the human congenital erythropoietic porphyria phenotype, including the characteristic light-induced cutaneous lesions.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2006</year>
                <volume>78</volume>
                <fpage>645</fpage>
                <lpage>58</lpage>
                <pub-id pub-id-type="pmid">16532394</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.boulechfar.1992.320">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boulechfar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Da Silva</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deybach</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordmann</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grandchamp</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Verneuil</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Heterogeneity of mutations in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria.</article-title>
                <source>Hum Genet.</source>
                <year>1992</year>
                <volume>88</volume>
                <fpage>320</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">1733834</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.da_khadahmane.2001.180">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Da&#x000ef;kha-Dahmane</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dommergues</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Narcy</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gubler</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dumez</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gauthier</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordmann</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nessmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terrasse</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Congenital erythropoietic porphyria: prenatal diagnosis and autopsy findings in two sibling fetuses.</article-title>
                <source>Pediatr Dev Pathol.</source>
                <year>2001</year>
                <volume>4</volume>
                <fpage>180</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11178635</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.dawe.2002.680">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dawe</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Du Vivier</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Creamer</surname>
                    <given-names>JD</given-names>
                  </name>
                </person-group>
                <article-title>Congenital erythropoietic porphyria: dilemmas in present day management.</article-title>
                <source>Clin Exp Dermatol.</source>
                <year>2002</year>
                <volume>27</volume>
                <fpage>680</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">12472546</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.de_verneuil.2008.615">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de Verneuil</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robert-Richard</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ged</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazurier</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moreau-Gaudry</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Successful gene therapy of mice with congenital erythropoietic porphyria.</article-title>
                <source>Med Sci (Paris)</source>
                <year>2008</year>
                <volume>24</volume>
                <fpage>615</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">18601879</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.desnick.2002.779">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astrin</surname>
                    <given-names>KH</given-names>
                  </name>
                </person-group>
                <article-title>Congenital erythropoietic porphyria: advances in pathogenesis and treatment.</article-title>
                <source>Br J Haematol.</source>
                <year>2002</year>
                <volume>117</volume>
                <fpage>779</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">12060112</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.desnick.1998.77">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glass</surname>
                    <given-names>IA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solis</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astrin</surname>
                    <given-names>KH</given-names>
                  </name>
                </person-group>
                <article-title>Molecular genetics of congenital erythropoietic porphyria.</article-title>
                <source>Semin Liver Dis.</source>
                <year>1998</year>
                <volume>18</volume>
                <fpage>77</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">9516681</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.di_pierro.2015.491">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Di Pierro</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karakas</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brancaleoni</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gambale</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurt</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winter</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Granata</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Czuchlewski</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langella</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iolascon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cappellini</surname>
                    <given-names>MD</given-names>
                  </name>
                </person-group>
                <article-title>Congenital erythropoietic porphyria linked to GATA1-R216W mutation: challenges for diagnosis.</article-title>
                <source>Eur J Haematol.</source>
                <year>2015</year>
                <volume>94</volume>
                <fpage>491</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">25251786</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.dupuisgirod.2005.104">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dupuis-Girod</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akkari</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ged</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galambrun</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keba&#x000ef;li</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deybach</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Claudy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geburher</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Philippe</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Verneuil</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertrand</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (G&#x000fc;nther disease).</article-title>
                <source>Eur J Pediatr.</source>
                <year>2005</year>
                <volume>164</volume>
                <fpage>104</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15703981</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.egan.2015.257">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Egan</surname>
                    <given-names>DN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phillips</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abkowitz</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <article-title>Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria.</article-title>
                <source>Blood.</source>
                <year>2015</year>
                <volume>126</volume>
                <fpage>257</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">25972160</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.faraci.2008.117">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Faraci</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morreale</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boeri</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lanino</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dallorso</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dini</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scuderi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cappelli</surname>
                    <given-names>B.</given-names>
                  </name>
                </person-group>
                <article-title>Unrelated HSCT in an adolescent affected by congenital erythropoietic porphyria.</article-title>
                <source>Pediatr Transplant.</source>
                <year>2008</year>
                <volume>12</volume>
                <fpage>117</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">18186900</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.fortian.2011.13127">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fortian</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonz&#x000e1;lez</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casta&#x000f1;o</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Falcon-Perez</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millet</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <article-title>Intracellular rescue of the uroporphyrinogen III synthase activity in enzymes carrying the hotspot mutation C73R.</article-title>
                <source>J Biol Chem.</source>
                <year>2011</year>
                <volume>286</volume>
                <fpage>13127</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">21343304</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.frank.1998.225">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Frank</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lam</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aita</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jugert</surname>
                    <given-names>FK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goerz</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merk</surname>
                    <given-names>HF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poh-Fitzpatrick</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christiano</surname>
                    <given-names>AM</given-names>
                  </name>
                </person-group>
                <article-title>C73R is a hotspot mutation in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria.</article-title>
                <source>Ann Hum Genet.</source>
                <year>1998</year>
                <volume>62</volume>
                <fpage>225</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">9803266</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.fritsch.1997.594">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fritsch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolsen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruzicka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goerz</surname>
                    <given-names>G.</given-names>
                  </name>
                </person-group>
                <article-title>Congenital erythropoietic porphyria.</article-title>
                <source>J Am Acad Dermatol.</source>
                <year>1997</year>
                <volume>36</volume>
                <fpage>594</fpage>
                <lpage>610</lpage>
                <pub-id pub-id-type="pmid">9092747</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.ged.2004.589">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ged</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e9;garban&#x000e9;</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chouery</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lalanne</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000e9;garban&#x000e9;</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Verneuil</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>Congenital erythropoietic porphyria: report of a novel mutation with absence of clinical manifestations in a homozygous mutant sibling.</article-title>
                <source>J Invest Dermatol.</source>
                <year>2004</year>
                <volume>123</volume>
                <fpage>589</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">15304101</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.hallai.2007.622">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hallai</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anstey</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mendelsohn</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans-Jones</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malick</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Badminton</surname>
                    <given-names>MN</given-names>
                  </name>
                </person-group>
                <article-title>Pregnancy in a patient with congenital erythropoietic porphyria.</article-title>
                <source>N Engl J Med.</source>
                <year>2007</year>
                <volume>357</volume>
                <fpage>622</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">17687144</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.harada.2001.279">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Harada</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shwayder</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lim</surname>
                    <given-names>HW</given-names>
                  </name>
                </person-group>
                <article-title>Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation.</article-title>
                <source>J Am Acad Dermatol.</source>
                <year>2001</year>
                <volume>45</volume>
                <fpage>279</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">11464191</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.katugampola.2012a.888">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Katugampola</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anstey</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finlay</surname>
                    <given-names>AY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whatley</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woolf</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mason</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deybach</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puy</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ged</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Verneuil</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanneken</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minder</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider-Yin</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Badminton</surname>
                    <given-names>MN</given-names>
                  </name>
                </person-group>
                <article-title>A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases.</article-title>
                <source>Br J Dermatol.</source>
                <year>2012a</year>
                <volume>167</volume>
                <fpage>888</fpage>
                <lpage>900</lpage>
                <pub-id pub-id-type="pmid">22804244</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.katugampola.2012b.901">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Katugampola</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Badminton</surname>
                    <given-names>MN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finlay</surname>
                    <given-names>AY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whatley</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woolf</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mason</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deybach</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puy</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ged</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Verneuil</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanneken</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minder</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider-Yin</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anstey</surname>
                    <given-names>AV</given-names>
                  </name>
                </person-group>
                <article-title>Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases.</article-title>
                <source>Br J Dermatol.</source>
                <year>2012b</year>
                <volume>167</volume>
                <fpage>901</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">22816431</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.kaufman.1967.210">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kaufman</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vickers</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rayne</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryan</surname>
                    <given-names>TJ</given-names>
                  </name>
                </person-group>
                <article-title>Congenital erythropoietic porphyria. Report of a case.</article-title>
                <source>Br J Dermatol.</source>
                <year>1967</year>
                <volume>79</volume>
                <fpage>210</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">6024737</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.kontos.2003.160">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kontos</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozog</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bichakjian</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lim</surname>
                    <given-names>HW</given-names>
                  </name>
                </person-group>
                <article-title>Congenital erythropoietic porphyria associated with myelodysplasia presenting in a 72-year-old man: report of a case and review of the literature.</article-title>
                <source>Br J Dermatol.</source>
                <year>2003</year>
                <volume>148</volume>
                <fpage>160</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">12534613</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.laorr.1994.307">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Laorr</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenspan</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Severe osteopenia in congenital erythropoietic porphyria.</article-title>
                <source>Can Assoc Radiol J.</source>
                <year>1994</year>
                <volume>45</volume>
                <fpage>307</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">8062123</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.oguz.1993.671">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Oguz</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sidal</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayram</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sansoy</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hekim</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Ocular involvement in two symptomatic congenital erythropoietic porphyria.</article-title>
                <source>Eur J Pediatr.</source>
                <year>1993</year>
                <volume>152</volume>
                <fpage>671</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">8404971</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.pain.1975.621">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pain</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Welch</surname>
                    <given-names>FW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woodroffe</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Handley</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lockwood</surname>
                    <given-names>WH</given-names>
                  </name>
                </person-group>
                <article-title>Erythropoietic uroporphyria of Gunther first presenting at 58 years with positive family studies.</article-title>
                <source>Br Med J.</source>
                <year>1975</year>
                <volume>3</volume>
                <fpage>621</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">1164638</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.phillips.2007.2618">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Phillips</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steensma</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pulsipher</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spangrude</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kushner</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <article-title>Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria.</article-title>
                <source>Blood.</source>
                <year>2007</year>
                <volume>109</volume>
                <fpage>2618</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">17148589</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.piomelli.1986.1029">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Piomelli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poh-Fitzpatrick</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seaman</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skolnick</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berdon</surname>
                    <given-names>WE</given-names>
                  </name>
                </person-group>
                <article-title>Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions.</article-title>
                <source>N Engl J Med.</source>
                <year>1986</year>
                <volume>314</volume>
                <fpage>1029</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">3960070</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.pohfitzpatrick.1988">
              <mixed-citation publication-type="book">Poh-Fitzpatrick MB, Piomelli S, Seaman C, Skolnick LM. Congenital erythropoietic porphyria: complete suppression of symptoms by long-term high-level transfusion with deferoxamine infusion iron rescue. In: Orfanos CE, Stadler R, Gollnick H, eds. <italic toggle="yes">Dermatology in Five Continents</italic>. Berlin, Germany: Springer Verlag; 1988:876-9.</mixed-citation>
            </ref>
            <ref id="cep.REF.pohfitzpatrick.1985">
              <mixed-citation publication-type="book">Poh-Fitzpatrick MB. Porphyrin sensitized cutaneous photosensitivity - pathogenesis and treatment. In: Disler PB, Moore MR, eds. <italic toggle="yes">Porphyria-Clinics in Dermatology</italic>. Philadelphia, PA: Lippincott; 1985:41-82.</mixed-citation>
            </ref>
            <ref id="cep.REF.pohfitzpatrick.1986.291">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Poh-Fitzpatrick</surname>
                    <given-names>MB</given-names>
                  </name>
                </person-group>
                <article-title>The erythropoietic porphyrias.</article-title>
                <source>Dermatol Clin.</source>
                <year>1986</year>
                <volume>4</volume>
                <fpage>291</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">3955899</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.sarkany.2011.1172">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sarkany</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ibbotson</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whatley</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawrence</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gover</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mufti</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masters</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Badminton</surname>
                    <given-names>MN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elder</surname>
                    <given-names>GH</given-names>
                  </name>
                </person-group>
                <article-title>Erythropoietic uroporphyria associated with myeloid malignancy is likely distinct from autosomal recessive congenital erythropoietic porphyria.</article-title>
                <source>J Invest Dermatol.</source>
                <year>2011</year>
                <volume>131</volume>
                <fpage>1172</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">21326293</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.schmid.1955.416">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schmid</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sundberg</surname>
                    <given-names>RD</given-names>
                  </name>
                </person-group>
                <article-title>Erythropoietic (congenital) porphyria: A rare abnormality of the normoblasts.</article-title>
                <source>Blood.</source>
                <year>1955</year>
                <volume>10</volume>
                <fpage>416</fpage>
                <lpage>28</lpage>
                <pub-id pub-id-type="pmid">14363322</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.shady.2002.980">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shady</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colby</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cunha</surname>
                    <given-names>LF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astrin</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bishop</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Congenital erythropoietic porphyria: identification and expression of eight novel mutations in the uroporphyrinogen III synthase gene.</article-title>
                <source>Br J Haematol.</source>
                <year>2002</year>
                <volume>117</volume>
                <fpage>980</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12060141</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.shaw.2001.101">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shaw</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancini</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McConnell</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kletzel</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literature.</article-title>
                <source>Bone Marrow Transplant.</source>
                <year>2001</year>
                <volume>27</volume>
                <fpage>101</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">11244446</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.siddique.2011.97">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Siddique</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez-Gonzalez</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thakuria</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>PY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foster</surname>
                    <given-names>CS</given-names>
                  </name>
                </person-group>
                <article-title>Scleral necrosis in a patient with congenital erythropoietic porphyria.</article-title>
                <source>Cornea.</source>
                <year>2011</year>
                <volume>30</volume>
                <fpage>97</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20847674</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.solis.2001.753">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Solis</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aizencang</surname>
                    <given-names>GI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astrin</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bishop</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria.</article-title>
                <source>J Clin Invest.</source>
                <year>2001</year>
                <month>Mar</month>
                <volume>107</volume>
                <fpage>753</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">11254675</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.stenson.2003.577">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stenson</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ball</surname>
                    <given-names>EV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mort</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phillips</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shiel</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>NS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abeysinghe</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krawczak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>DN</given-names>
                  </name>
                </person-group>
                <article-title>Human Gene Mutation Database (HGMD): 2003 update.</article-title>
                <source>Hum Mutat.</source>
                <year>2003</year>
                <volume>21</volume>
                <fpage>577</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">12754702</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.taibjee.2007.567">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Taibjee</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevenson</surname>
                    <given-names>OE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdullah</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tan</surname>
                    <given-names>CY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darbyshire</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moss</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodyear</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heagerty</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whatley</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Badminton</surname>
                    <given-names>MN</given-names>
                  </name>
                </person-group>
                <article-title>Allogeneic bone marrow transplantation in a 7-year-old girl with congenital erythropoietic porphyria: a treatment dilemma.</article-title>
                <source>Br J Dermatol.</source>
                <year>2007</year>
                <volume>156</volume>
                <fpage>567</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">17300251</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.tezcan.1998.4053">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tezcan</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gurgey</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuncer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cetin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oner</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yetgin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ersoy</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aizencang</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astrin</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Congenital erythropoietic porphyria successfully treated by allogeneic bone marrow transplantation.</article-title>
                <source>Blood.</source>
                <year>1998</year>
                <volume>92</volume>
                <fpage>4053</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9834209</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.thomas.1996.453">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ged</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nordmann</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Verneuil</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pellier</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanche</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Correction of congenital erythropoietic porphyria by bone marrow transplantation.</article-title>
                <source>J Pediatr.</source>
                <year>1996</year>
                <volume>129</volume>
                <fpage>453</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">8804339</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.tishler.1990.645">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tishler</surname>
                    <given-names>PV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winston</surname>
                    <given-names>SH</given-names>
                  </name>
                </person-group>
                <article-title>Rapid improvement in the chemical pathology of congenital erythropoietic porphyria with treatment with superactivated charcoal.</article-title>
                <source>Methods Find Exp Clin Pharmacol.</source>
                <year>1990</year>
                <volume>12</volume>
                <fpage>645</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">2084460</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.tofigueras.2011.1443">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>To-Figueras</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ducamp</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Badenas</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delaby</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ged</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lyoumi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gouya</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Verneuil</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beaumont</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreira</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deybach</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herrero</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puy</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria.</article-title>
                <source>Blood.</source>
                <year>2011</year>
                <volume>118</volume>
                <fpage>1443</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">21653323</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.venkatesh.2000.314">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Venkatesh</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garg</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumaran</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tewari</surname>
                    <given-names>HK</given-names>
                  </name>
                </person-group>
                <article-title>Congenital porphyria with necrotizing scleritis in a 9-year-old child.</article-title>
                <source>Clin Experiment Ophthalmol.</source>
                <year>2000</year>
                <volume>28</volume>
                <fpage>314</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11021563</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.wahlin.2008.1340">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wahlin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Srikanthan</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamre</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harper</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brun</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria.</article-title>
                <source>Liver Transpl.</source>
                <year>2008</year>
                <volume>14</volume>
                <fpage>1340</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18756472</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.warner.1992.693">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Warner</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoo</surname>
                    <given-names>HW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Congenital erythropoietic porphyria: identification and expression of exonic mutations in the uroporphyrinogen III synthase gene.</article-title>
                <source>J Clin Invest.</source>
                <year>1992</year>
                <volume>89</volume>
                <fpage>693</fpage>
                <lpage>700</lpage>
                <pub-id pub-id-type="pmid">1737856</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.weston.1978.921">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weston</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholson</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lim</surname>
                    <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macdonald</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henderson</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Congenital erythropoietic uroporphyria (G&#x000fc;nther's disease) presenting in a middle aged man.</article-title>
                <source>Int J Biochem.</source>
                <year>1978</year>
                <volume>9</volume>
                <fpage>921</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">744297</pub-id>
              </element-citation>
            </ref>
            <ref id="cep.REF.zixkieffer.1996.217">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zix-Kieffer</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eyer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acar</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Racadot</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlaeder</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oberlin</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lutz</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Successful cord blood stem cell transplantation for congenital erythropoietic porphyria (Gunther's disease).</article-title>
                <source>Bone Marrow Transplant.</source>
                <year>1996</year>
                <volume>18</volume>
                <fpage>217</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">8832020</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="cep.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="cep.Acknowledgments">
          <title>Acknowledgments</title>
          <p>The CEP contribution to <italic toggle="yes">GeneReviews</italic> was supported in part by the Porphyrias Consortium of the NIH-supported <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://rarediseasesnetwork.epi.usf.edu/">Rare Diseases Clinical Research Network</ext-link> (NIH grant: 5 U54 DK083909), including:</p>
          <list list-type="bullet">
            <list-item>
              <p>Dr Karl Anderson, University of Texas Medical Branch, Galveston, TX</p>
            </list-item>
            <list-item>
              <p>Dr Montgomery Bissell, University of California, San Francisco, CA</p>
            </list-item>
            <list-item>
              <p>Dr Joseph Bloomer, University of Alabama, Birmingham, AL</p>
            </list-item>
            <list-item>
              <p>Dr Herbert Bonkovsky, Wake Forest University Health Sciences, Winston-Salem, NC</p>
            </list-item>
            <list-item>
              <p>Dr Robert J Desnick, Icahn School of Medicine at Mount Sinai, New York, NY</p>
            </list-item>
            <list-item>
              <p>Dr John Phillips, University of Utah School of Medicine, Salt Lake City, UT</p>
            </list-item>
          </list>
        </sec>
        <sec id="cep.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>7 April 2016 (bp) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>12 September 2013 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>5 March 2013 (ae) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
